A Meta-Analytic Review of Polyunsaturated Fatty Acid Compositions in Patients with Depression

Lin, Pin‐Yao; Huang, Shih‐Yi; Su, Kuan‐Pin

doi:10.1016/j.biopsych.2010.03.018

Cited by 470 publications

(365 citation statements)

References 67 publications

Supporting

Mentioning

336

Contrasting

Unclassified

Order By: Relevance

“…Cross-sectional studies in several psychiatric disorders generally show associations with a pattern of decreased concentrations of omega-3 fatty acids, and an increased omega-6/omega-3-ratio (Freeman 2000;Haag 2003). Evidence seems to be strongest for major depressive disorder (Lin et al 2010), but a similar pattern seems to exist for schizophrenia . Anxiety disorders are less extensively studied (Ross 2009;de Vries et al 2016); we previously found lower DHA in PTSD patients compared to controls, but only after correction for diet (de Vries et al 2016).…”

Section: Associations Between Fatty Acid Alterations and Psychiatric mentioning

confidence: 99%

“…Importantly, several negative findings have been published as well (Lin et al 2010;Hoen et al 2013;Mocking et al 2015;Medema et al 2016). A wide range of methodological issues could explain these inconsistencies.…”

Section: Associations Between Fatty Acid Alterations and Psychiatric mentioning

confidence: 99%

“…One important lifestyle factor is diet. Not all studies apply standard corrections for dietary intake (Lin et al 2010). In addition, diet is difficult to measure and residual confounding after correction could still influence results.…”

Section: Associations Between Fatty Acid Alterations and Psychiatric mentioning

confidence: 99%

“…Some studies investigated fatty acids exclusively in medication free subjects (Lin et al 2010;Mocking et al 2015Mocking et al , 2017a, but in general the precise effects of the different medications on fatty acid concentrations have not been systematically studied in psychiatric patients. Nevertheless, the relation between metabolic alterations and psychiatric diseases was already observed well before the development of psychotropic medication (Assies et al 2014).…”

Section: Associations Between Fatty Acid Alterations and Psychiatric mentioning

confidence: 99%

See 3 more Smart Citations

Focus on fatty acids in the neurometabolic pathophysiology of psychiatric disorders

Mocking

Assies

Ruhé

et al. 2018

J of Inher Metab Disea

View full text Add to dashboard Cite

Continuous research into the pathophysiology of psychiatric disorders, such as major depressive disorder (MDD), posttraumatic stress disorder (PTSD), and schizophrenia, suggests an important role for metabolism. This narrative review will provide an upto-date summary of how metabolism is thought to be involved in the pathophysiology of these psychiatric disorders. We will focus on (I) the important role of fatty acids in these metabolic alterations, (II) whether fatty acid alterations represent epiphenomena or risk factors, and (III) similarities and dissociations in fatty acid alterations between different psychiatric disorders. (Historical) epidemiological evidence links fatty acid intake to psychiatric disorder prevalence, corroborated by altered fatty acid concentrations measured in psychiatric patients. These fatty acid alterations are connected with other concomitant pathophysiological mechanisms, including biological stress (hypothalamic-pituitary-adrenal (HPA)-axis and oxidative stress), inflammation, and brain network structure and function. Metabolomics and lipidomics studies are underway to more deeply investigate this complex network of associated neurometabolic alterations. Supplementation of fatty acids as disease-modifying nutraceuticals has clinical potential, particularly add-on eicosapentaenoic acid (EPA) in depressed patients with markers of increased inflammation. However, by interpreting the observed fatty acid alterations as partly (mal)adaptive phenomena, we attempt to nuance translational expectations and provide new clinical applications for these novel neurometabolic insights, e.g., to predict treatment response or depression recurrence. In conclusion, placing fatty acids in context can contribute to further understanding and optimized treatment of psychiatric disorders, in order to diminish their overwhelming burden of disease.

show abstract

Section: Associations Between Fatty Acid Alterations and Psychiatric mentioning

confidence: 99%

Section: Associations Between Fatty Acid Alterations and Psychiatric mentioning

confidence: 99%

Section: Associations Between Fatty Acid Alterations and Psychiatric mentioning

confidence: 99%

Section: Associations Between Fatty Acid Alterations and Psychiatric mentioning

confidence: 99%

See 2 more Smart Citations

Focus on fatty acids in the neurometabolic pathophysiology of psychiatric disorders

Mocking

Assies

Ruhé

et al. 2018

J of Inher Metab Disea

View full text Add to dashboard Cite

show abstract

“…Epidemiological studies [5,6], case-control studies [7][8][9][10][11][12] , and clinical trials [13][14][15][16][17][18] all suggest that n-3 PUFAs might play an important role in major depressive disorder (MDD). Moreover, genotypes of the key enzymes for phospholipids metabolism, such as Phospholipase A2 (PLA2) and cyclo-oxygenase-2 (COX-2), have been associated with major depressive disorder [19,20] and Interferon (IFN)-α induced depression [21].…”

Section: Introductionmentioning

confidence: 99%

BanI polymorphism of cytosolic phospholipase A2 gene and somatic symptoms in medication-free acute depressed patients

Chang

Guu

Chen

et al. 2018

Prostaglandins, Leukotrienes and Essential Fatty Acids

Self Cite

View full text Add to dashboard Cite

Somatic symptoms are commonly seen in patients with major depressive disorder (MDD) and might be associated with inflammatory activation. Cytosolic phospholipase A2 (cPLA2) and cyclo-oxygenase-2 (COX-2) are the key enzymes in the metabolism of polyunsaturated fatty acids (PUFAs), which in turn may play an important role in inflammation and somatic symptoms in depression. This study investigated the effects of BanI polymorphism of cPLA2 gene and COX-2 rs4648308 genotypes on somatic symptoms and inflammatory marker in patients with MDD.Eighty-two patients with MDD were assessed for their psychopathology including 2 psychiatric and somatic symptoms, BanI polymorphism of cPLA2 and COX-2 rs4648308 genotypes and CRP levels. The results revealed that MDD patients with the cPLA2 BanI GG genotypes had higher somatic symptoms and higher levels of C-reactive protein (CRP), while no differences were found among the COX-2 rs4648308 genotypes. Inflammatory process, such as arachidonic acid cascade pathway, might help explain the effect of cPLA2 BanI polymorphism on the somatic symptoms, and may be a potential target for future investigation on treatment for MDD with somatic symptoms. However, the interpretation of the findings in this study is limited since we analyzed the data from a subset data from a larger study.

show abstract

Association of Use of Omega-3 Polyunsaturated Fatty Acids With Changes in Severity of Anxiety Symptoms

Tseng²,

Lin

et al. 2018

JAMA Netw Open

Self Cite

106

View full text Add to dashboard Cite

Key Points Question Is omega-3 polyunsaturated fatty acid treatment associated with an improvement in anxiety symptoms? Findings In this systematic review and meta-analysis of 19 clinical trials including 2240 participants from 11 countries, improvement in anxiety symptoms was associated with omega-3 polyunsaturated fatty acid treatment compared with controls in both placebo-controlled and non–placebo-controlled trials. The anxiolytic effects of omega-3 polyunsaturated fatty acids were also stronger in participants with clinical conditions than in subclinical populations. Meaning Omega-3 polyunsaturated fatty acid treatment for anxiety might be effective in clinical settings.

show abstract

A Meta-Analytic Review of Polyunsaturated Fatty Acid Compositions in Patients with Depression

Cited by 470 publications

References 67 publications

Focus on fatty acids in the neurometabolic pathophysiology of psychiatric disorders

Focus on fatty acids in the neurometabolic pathophysiology of psychiatric disorders

BanI polymorphism of cytosolic phospholipase A2 gene and somatic symptoms in medication-free acute depressed patients

Association of Use of Omega-3 Polyunsaturated Fatty Acids With Changes in Severity of Anxiety Symptoms

Contact Info

Product

Resources

About